The Metabolic Syndrome Institute Literature Watch features the latest articles on the metabolic syndrome. Click on the links below to view the abstracts for each article.

Adiponectin

• Araki S, Dobashi K, Kubo K, Asayama K, Shirahata A.
  High molecular weight, rather than total, adiponectin levels better reflect metabolic abnormalities associated with childhood obesity.
  J Clin Endocrinol Metab. 2006 Dec;91(12):5113-6. Epub 2006 Sep 19.
• Azar RR, Sarkis A, Salameh E, Gannage-Yared MH, Amm-Azar M, Badaoui G, Germanos M, Kassab R.
  Percutaneous coronary intervention increases leptin and decreases adiponectin levels.
  Clin Endocrinol (Oxf). 2006 Dec;65(6):712-6.
• Elbatarny HS, Netherton SJ, Ovens JD, Ferguson AV, Maurice DH.
  Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: Implication in obesity-associated cardiovascular diseases.
  Eur J Pharmacol. 2006 Dec 1; [Epub ahead of print]
• Gilardini L, McTernan PG, Girola A, da Silva NF, Alberti L, Kumar S, Invitti C.
  Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents.
  Atherosclerosis. 2006 Dec;189(2):401-7. Epub 2006 Jan 25.
• Mao X, Hong JY, Dong LQ.
  The adiponectin signaling pathway as a novel pharmacological target.
  Mini Rev Med Chem. 2006 Dec;6(12):1331-40.
• Szmitko PE, Teoh H, Stewart DJ, Verma S.
  Adiponectin and cardiovascular disease.
  Am J Physiol Heart Circ Physiol. 2006 Dec 1; [Epub ahead of print]

back to top

Cardiovascular disease

• Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C.
  Metabolic syndrome, low-density lipoprotein cholesterol, and risk of cardiovascular disease: a population-based study.
  Atherosclerosis. 2006 Dec;189(2):369-74. Epub 2006 Jan 23.
• The DECODE Study Group; Qiao Q.
  Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women.
  Diabetologia. 2006 Dec;49(12):2837-46. Epub 2006 Oct 5.
• Reis EC, Kip KE, Marroquin OC, Kiesau M, Hipps L Jr, Peters RE, Reis SE.
  Screening children to identify families at increased risk for cardiovascular disease.
  Pediatrics. 2006 Dec;118(6):e1789-97.
• Roberts CK, Ng C, Hama S, Eliseo AJ, Barnard RJ.
  Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors.
  J Appl Physiol. 2006 Dec;101(6):1727-32. Epub 2006 Aug 10.
• Stein AD, Wang M, Ramirez-Zea M, Flores R, Grajeda R, Melgar P, Ramakrishnan U, Martorell R.
  Exposure to a nutrition supplementation intervention in early childhood and risk factors for cardiovascular disease in adulthood: evidence from Guatemala.
  Am J Epidemiol. 2006 Dec 15;164(12):1160-70. Epub 2006 Oct 3.
  

back to top

Diabetes

• Adachi Y, Yoshida J, Kodera Y, Kiss T, Jakusch T, Enyedy EA, Yoshikawa Y, Sakurai H.
  Oral administration of a zinc complex improves type 2 diabetes and metabolic syndromes.
  Biochem Biophys Res Commun. 2006 Dec 8;351(1):165-70. Epub 2006 Oct 11.
• Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, Sowers J; STAR Investigators.
  Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
  Diabetes Care. 2006 Dec;29(12):2592-7.
• Bari MR, Johan Ostgren C, Rastam L, Lindblad U.
  Abdominal obesity and insulin resistance in patients with type 2 diabetes in a Swedish community. Skaraborg hypertension and diabetes project.
  Scand J Prim Health Care. 2006 Dec;24(4):211-7.
• Metascreen Writing Committee; Bonadonna RC, Cucinotta D, Fedele D, Riccardi G, Tiengo A.
  The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey.
  Diabetes Care. 2006 Dec;29(12):2701-7.
• Fievet C, Fruchart JC, Staels B.
  PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
  Curr Opin Pharmacol. 2006 Dec;6(6):606-14. Epub 2006 Sep 14.
• Melzer D, Murray A, Hurst AJ, Weedon MN, Bandinelli S, Corsi AM, Ferrucci L, Paolisso G, Guralnik JM, Frayling TM.
  Effects of the diabetes linked TCF7L2 polymorphism in a representative older population.
  BMC Med. 2006 Dec 20;4:34.
• Raeder MB, Bjelland I, Emil Vollset S, Steen VM.
  Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study.
  J Clin Psychiatry. 2006 Dec;67(12):1974-82.
• Salek RM, Maguire ML, Bentley E, Rubtsov DV, Hough T, Cheeseman M, Nunez DJ, Sweatman BC, Haselden JN, Cox R, Connor SC, Griffin JL.
  A metabolic comparison of urinary changes in type 2 diabetes in mouse, rat and man.
  Physiol Genomics. 2006 Dec 26; [Epub ahead of print]
• Thanopoulou A, Karamanos B, Angelico F, Assaad-Khalil S, Djordjevic P, Katsilambros N, Migdalis I, Mrabet M, Petkova M, Roussi D, Tenconi MT, Archimandritis A.
  Epidemiological evidence for the non-random clustering of the components of the metabolic syndrome: multicentre study of the Mediterranean Group for the Study of Diabetes.
  Eur J Clin Nutr. 2006 Dec;60(12):1376-83. Epub 2006 Jul 5.
• Viberti G, Lachin J, Holman R, Zinman B, Haffner S, Kravitz B, Heise MA, Jones NP, O'Neill MC, Freed MI, Kahn SE, Herman WH; for the ADOPT Study Group.
  A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe.
  Diabet Med. 2006 Dec;23(12):1289-94.
  

back to top

Diet, Nutrition and Metabolism

• Blaak EE.
  Prevention and treatment of obesity and related complications: a role for protein?
  Int J Obes (Lond). 2006 Dec;30 Suppl 3:S24-7.
• Brake DK, Smith EO, Mersmann H, Smith CW, Robker RL.
  ICAM-1 expression in adipose tissue: effects of diet-induced obesity in mice.
  Am J Physiol Cell Physiol. 2006 Dec;291(6):C1232-9. Epub 2006 Jun 28.
• Esmaillzadeh A, Kimiagar M, Mehrabi Y, Azadbakht L, Hu FB, Willett WC.
  Fruit and vegetable intakes, C-reactive protein, and the metabolic syndrome.
  Am J Clin Nutr. 2006 Dec;84(6):1489-97.
• Gallou-Kabani C, Vige A, Gross MS, Boileau C, Rabes JP, Fruchart-Najib J, Jais JP, Junien C.
  Resistance to high-fat diet in the female progeny of obese mice fed a control diet during the periconceptual, gestation and lactation periods.
  Am J Physiol Endocrinol Metab. 2006 Dec 12; [Epub ahead of print]
• Glueck CJ, Aregawi D, Agloria M, Winiarska M, Sieve L, Wang P.
  Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome.
  Metabolism. 2006 Dec;55(12):1582-9.
• Hallikainen M, Toppinen L, Mykkanen H, Agren JJ, Laaksonen DE, Miettinen TA, Niskanen L, Poutanen KS, Gylling H.
  Interaction between cholesterol and glucose metabolism during dietary carbohydrate modification in subjects with the metabolic syndrome.
  Am J Clin Nutr. 2006 Dec;84(6):1385-92.
• Roberts CK, Ng C, Hama S, Eliseo AJ, Barnard RJ.
  Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors.
  J Appl Physiol. 2006 Dec;101(6):1727-32. Epub 2006 Aug 10.
• Takemoto T, Nishio Y, Sekine O, Ikeuchi C, Nagai Y, Maeno Y, Maegawa H, Kimura H, Kashiwagi A.
  RBMX is a novel hepatic transcriptional regulator of SREBP-1c gene response to high-fructose diet.
  FEBS Lett. 2006 Dec 14; [Epub ahead of print]
• Thanopoulou A, Karamanos B, Angelico F, Assaad-Khalil S, Djordjevic P, Katsilambros N, Migdalis I, Mrabet M, Petkova M, Roussi D, Tenconi MT, Archimandritis A.
  Epidemiological evidence for the non-random clustering of the components of the metabolic syndrome: multicentre study of the Mediterranean Group for the Study of Diabetes.
  Eur J Clin Nutr. 2006 Dec;60(12):1376-83. Epub 2006 Jul 5.
• Villareal DT, Miller BV 3rd, Banks M, Fontana L, Sinacore DR, Klein S.
  Effect of lifestyle intervention on metabolic coronary heart disease risk factors in obese older adults.
  Am J Clin Nutr. 2006 Dec;84(6):1317-23.
• Wannamethee SG, Shaper AG, Whincup PH.
  Modifiable lifestyle factors and the metabolic syndrome in older men: Effects of lifestyle changes.
  J Am Geriatr Soc. 2006 Dec;54(12):1909-14.

back to top

Drug Therapy

• Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, Sowers J; STAR Investigators.
  Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
  Diabetes Care. 2006 Dec;29(12):2592-7.
• Chu MC, Cosper P, Nakhuda GS, Lobo RA.
  A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome.
  Fertil Steril. 2006 Dec;86(6):1669-75. Epub 2006 Oct 30.
• De Hert M, Kalnicka D, van Winkel R, Wampers M, Hanssens L, Van Eyck D, Scheen A, Peuskens J.
  Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder.
  J Clin Psychiatry. 2006 Dec;67(12):1889-96.
• Fujioka K.
  Metabolic syndrome treatment strategies.
  Pharmacotherapy. 2006 Dec;26(12 Pt 2):222S-6S.
• Nakano S, Inada Y, Masuzaki H, Tanaka T, Yasue S, Ishii T, Arai N, Ebihara K, Hosoda K, Maruyama K, Yamazaki Y, Shibata N, Nakao K.
  Bezafibrate regulates the expression and enzyme activity of 11{beta}-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.
  Am J Physiol Endocrinol Metab. 2006 Dec 26; [Epub ahead of print]
• Turpin SM, Lancaster GI, Darby I, Febbraio MA, Watt MJ.
  Apoptosis in skeletal muscle myotubes is induced by ceramides and is positively related to insulin resistance.
  Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1341-50. Epub 2006 Jul 18.
• Wierzbicki AS.
  Rimonabant: endocannabinoid inhibition for the metabolic syndrome.
  Int J Clin Pract. 2006 Dec;60(12):1697-706.

back to top

Epidemiology

• Doro AR, Gimeno SG, Hirai AT, Franco LJ, Ferreira SR.
  [Analysis on the association of physical activity with metabolic syndrome in a population-based study of Japanese-Brazilians.]
  Arq Bras Endocrinol Metabol. 2006 Dec;50(6):1066-74. Portuguese.
• Gause-Nilsson I, Gherman S, Kumar Dey D, Kennerfalk A, Steen B.
  Prevalence of metabolic syndrome in an elderly Swedish population.
  Acta Diabetol. 2006 Dec;43(4):120-6.
• Jacobson DL, Tang AM, Spiegelman D, Thomas AM, Skinner S, Gorbach SL, Wanke C.
  Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey).
  J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):458-66.
• Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C.
  Metabolic syndrome, low-density lipoprotein cholesterol, and risk of cardiovascular disease: a population-based study.
  Atherosclerosis. 2006 Dec;189(2):369-74. Epub 2006 Jan 23.
• Kim JA, Choi CJ, Yum KS.
  Cut-off values of visceral fat area and waist circumference: diagnostic criteria for abdominal obesity in a Korean population.
  J Korean Med Sci. 2006 Dec;21(6):1048-53.
• Melzer D, Murray A, Hurst AJ, Weedon MN, Bandinelli S, Corsi AM, Ferrucci L, Paolisso G, Guralnik JM, Frayling TM.
  Effects of the diabetes linked TCF7L2 polymorphism in a representative older population.
  BMC Med. 2006 Dec 20;4:34.

back to top

Exercise & Physical Activity

• Gayda M, Brun C, Juneau M, Levesque S, Nigam A.
  Long-term cardiac rehabilitation and exercise training programs improve metabolic parameters in metabolic syndrome patients with and without coronary heart disease.
  Nutr Metab Cardiovasc Dis. 2006 Dec 1; [Epub ahead of print]
• Li CL, Lin JD, Lee SJ, Tseng RF.
  Associations between the metabolic syndrome and its components, watching television and physical activity.
  Public Health. 2006 Dec 22; [Epub ahead of print]
• Roberts CK, Ng C, Hama S, Eliseo AJ, Barnard RJ.
  Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors.
  J Appl Physiol. 2006 Dec;101(6):1727-32. Epub 2006 Aug 10.
• Ruderman NB, Keller C, Richard AM, Saha AK, Luo Z, Xiang X, Giralt M, Ritov VB, Menshikova EV, Kelley DE, Hidalgo J, Pedersen BK, Kelly M.
  Interleukin-6 Regulation of AMP-Activated Protein Kinase: Potential Role in the Systemic Response to Exercise and Prevention of the Metabolic Syndrome.
  Diabetes. 2006 Dec;55 Suppl 2:S48-54.
• Zhang JQ, Ji LL, Fretwell VS, Nunez G.
  Effect of exercise on postprandial lipemia in men with hypertriglyceridemia.
  Eur J Appl Physiol. 2006 Dec;98(6):575-82. Epub 2006 Sep 28.

back to top

Genetics

• Degenhardt T, Matilainen M, Herzig KH, Dunlop TW, Carlberg C.
  The insulin-like growth factor-binding protein 1 gene is a primary target of peroxisome proliferator-activated receptors.
  J Biol Chem. 2006 Dec 22;281(51):39607-19. Epub 2006 Oct 24.
• Hu T, Chouinard M, Cox AL, Sipes P, Marcelo M, Ficorilli J, Li S, Gao H, Ryan TP, Michael MD, Michael LF.
  Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation.
  J Biol Chem. 2006 Dec 29;281(52):39831-8. Epub 2006 Oct 25.
• Kempf K, Rose B, Herder C, Haastert B, Fusbahn-Laufenburg A, Reifferscheid A, Scherbaum WA, Kolb H, Martin S.
  The metabolic syndrome sensitizes leukocytes for glucose-induced immune gene expression.
  J Mol Med. 2006 Dec 12; [Epub ahead of print]
• Lin S, Saxena NK, Ding X, Stein LL, Anania FA.
  Leptin increases tissue inhibitor of metalloproteinase I (TIMP-1) gene expression by a specificity protein 1/signal transducer and activator of transcription 3 mechanism.
  Mol Endocrinol. 2006 Dec;20(12):3376-88. Epub 2006 Aug 24.
• Lindholm E, Melander O, Almgren P, Berglund G, Agardh CD, Groop L, Orho-Melander M.
  Polymorphism in the MHC2TA Gene Is Associated with Features of the Metabolic Syndrome and Cardiovascular Mortality.
  PLoS ONE. 2006 Dec 20;1:e64.
• Ptitsyn A, Hulver M, Cefalu W, York D, Smith SR.
  Unsupervised clustering of gene expression data points at hypoxia as possible trigger for metabolic syndrome.
  BMC Genomics. 2006 Dec 19;7:318.
• Teran-Garcia M, Despres JP, Tremblay A, Bouchard C.
  Effects of cholesterol ester transfer protein (CETP) gene on adiposity in response to long-term overfeeding.
  Atherosclerosis. 2006 Dec 27; [Epub ahead of print]
  
  

back to top

Hypertension

• Egan BM, Lackland DT, Igho-Pemu P, Hendrix KH, Basile J, Rehman SU, Okonofua EC, Quarshie A, Oduwole A, Onwuanyi A, Reed J, Obialo C, Ofili EO.
  Cardiovascular risk factor control in communities--update from the ASH Carolinas-Georgia Chapter, the Hypertension Initiative, and the Community Physicians' Network.
  J Clin Hypertens (Greenwich). 2006 Dec;8(12):879-86.
• Gomez P, Ruilope LM, Barrios V, Navarro J, Prieto MA, Gonzalez O, Guerrero L, Zamorano MA, Filozof C.
  Prevalence of Renal Insufficiency in Individuals with Hypertension and Obesity/Overweight: The FATH Study.
  J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S194-200.
• Heinig M, Johnson RJ.
  Role of uric acid in hypertension, renal disease, and metabolic syndrome.
  Cleve Clin J Med. 2006 Dec;73(12):1059-64.
• Krishnan E, Kwoh CK, Schumacher HR, Kuller L.
  Hyperuricemia and Incidence of Hypertension Among Men Without Metabolic Syndrome.
  Hypertension. 2006 Dec 26; [Epub ahead of print]
• Potenza MA, Marasciulo FL, Tarquinio M, Quon MJ, Montagnani M.
  Treatment of spontaneously hypertensive rats with rosiglitazone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement in hypertension and insulin resistance.
  Diabetes. 2006 Dec;55(12):3594-603.

back to top

Insulin Sensitivity

• Amato MC, Galluzzo A, Merlino S, Mattina A, Richiusa P, Criscimanna A, Giordano C.
  Lower insulin sensitivity differentiates hirsute from non-hirsute Sicilian women with polycystic ovary syndrome.
  Eur J Endocrinol. 2006 Dec;155(6):859-65.
• Antoine HJ, Pall M, Trader BC, Chen YD, Azziz R, Goodarzi MO.
  Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome.
  Fertil Steril. 2006 Dec 1; [Epub ahead of print]
• Cupisti A, Meola M, D'Alessandro C, Bernabini G, Pasquali E, Carpi A, Barsotti G.
  Insulin resistance and low urinary citrate excretion in calcium stone formers.
  Biomed Pharmacother. 2006 Dec 4; [Epub ahead of print]
• de Vinuesa SG, Goicoechea M, Kanter J, Puerta M, Cachofeiro V, Lahera V, Gomez-Campdera F, Luno J.
  Insulin Resistance, Inflammatory Biomarkers, and Adipokines in Patients with Chronic Kidney Disease: Effects of Angiotensin II Blockade.
  J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S206-12.
• Dulloo AG, Jacquet J, Seydoux J, Montani JP.
  The thrifty 'catch-up fat' phenotype: its impact on insulin sensitivity during growth trajectories to obesity and metabolic syndrome.
  Int J Obes (Lond). 2006 Dec;30 Suppl 4:S23-35.
• Glueck CJ, Aregawi D, Agloria M, Winiarska M, Sieve L, Wang P.
  Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome.
  Metabolism. 2006 Dec;55(12):1582-9.
• Kawai T, Ito T, Ohwada K, Mera Y, Matsushita M, Tomoike H.
  Hereditary postprandial hypertriglyceridemic rabbit exhibits insulin resistance and central obesity: a novel model of metabolic syndrome.
  Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2752-7. Epub 2006 Sep 21.
• Misra A, Madhavan M, Vikram NK, Pandey RM, Dhingra V, Luthra K.
  Simple anthropometric measures identify fasting hyperinsulinemia and clustering of cardiovascular risk factors in Asian Indian adolescents.
  Metabolism. 2006 Dec;55(12):1569-73.
• Potenza MA, Marasciulo FL, Tarquinio M, Quon MJ, Montagnani M.
  Treatment of spontaneously hypertensive rats with rosiglitazone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement in hypertension and insulin resistance.
  Diabetes. 2006 Dec;55(12):3594-603.
  

back to top

Lipoproteins

• Dugue-Pujol S, Rousset X, Pastier D, Quang NT, Pautre V, Chambaz J, Chabert M, Kalopissis AD.
  Human apolipoprotein A-II associates with triglyceride-rich lipoproteins in plasma and impairs their catabolism.
  J Lipid Res. 2006 Dec;47(12):2631-9. Epub 2006 Sep 21.

back to top

Nitric Oxide

• Raij L.
  Nitric oxide in the pathogenesis of cardiac disease.
  J Clin Hypertens (Greenwich). 2006 Dec;8(12 Suppl 4):30-9.
  PMID: 17170604 [PubMed - in process]
  

back to top

Non-Alcoholic Fatty Liver Disease

• Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ.
  Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease.
  Diabetes Metab Res Rev. 2006 Nov-Dec;22(6):437-43. Review.

back to top

Obesity

• Despres JP, Lemieux I.
  Abdominal obesity and metabolic syndrome.
  Nature. 2006 Dec 14;444(7121):881-7. Review.
• Gomez P, Ruilope LM, Barrios V, Navarro J, Prieto MA, Gonzalez O, Guerrero L, Zamorano MA, Filozof C.
  Prevalence of Renal Insufficiency in Individuals with Hypertension and Obesity/Overweight: The FATH Study.
  J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S194-200.
• Liew PL, Lee WJ, Lee YC, Wang HH, Wang W, Lin YC.
  Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
  Obes Surg. 2006 Dec;16(12):1584-93.
• Parikh RM, Joshi SR, Menon PS, Shah NS.
  Index of central obesity - A novel parameter.
  Med Hypotheses. 2006 Dec 5; [Epub ahead of print]
• Raeder MB, Bjelland I, Emil Vollset S, Steen VM.
  Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study.
  J Clin Psychiatry. 2006 Dec;67(12):1974-82.
• Schilder RJ, Marden JH.
  Metabolic syndrome and obesity in an insect.
  Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18805-9. Epub 2006 Nov 28.
• Sharma AM, Staels B.
  Peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) and adipose tissue -- understanding obesity-related changes in regulation of lipid and glucose metabolism.
  J Clin Endocrinol Metab. 2006 Dec 5; [Epub ahead of print]
• Sorensen GL, Hjelmborg JV, Leth-Larsen R, Schmidt V, Fenger M, Poulain F, Hawgood S, Sorensen TI, Kyvik KO, Holmskov U.
  Surfactant protein D of the innate immune defence is inversely associated with human obesity and SP-D deficiency infers increased body weight in mice.
  Scand J Immunol. 2006 Dec;64(6):633-8.
• Taylor PD, Poston L.
  Developmental programming of obesity.
  Exp Physiol. 2006 Dec 14; [Epub ahead of print]
• Van Guilder GP, Hoetzer GL, Greiner JJ, Stauffer BL, Desouza CA.
  Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults.
  Obesity (Silver Spring). 2006 Dec;14(12):2127-31.

back to top

PCOS / Menopause / Metabolic Syndrome in Women

• Amato MC, Galluzzo A, Merlino S, Mattina A, Richiusa P, Criscimanna A, Giordano C.
  Lower insulin sensitivity differentiates hirsute from non-hirsute Sicilian women with polycystic ovary syndrome.
  Eur J Endocrinol. 2006 Dec;155(6):859-65.
• Antoine HJ, Pall M, Trader BC, Chen YD, Azziz R, Goodarzi MO.
  Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome.
  Fertil Steril. 2006 Dec 1; [Epub ahead of print]
• Chu MC, Cosper P, Nakhuda GS, Lobo RA.
  A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome.
  Fertil Steril. 2006 Dec;86(6):1669-75. Epub 2006 Oct 30.
• Glueck CJ, Aregawi D, Agloria M, Winiarska M, Sieve L, Wang P.
  Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome.
  Metabolism. 2006 Dec;55(12):1582-9.
• Ireland K, Child T.
  Polycystic ovary syndrome and the postmenopausal woman.
  J Br Menopause Soc. 2006 Dec;12(4):143-8.
• Joffe H, Cohen LS, Suppes T, Hwang CH, Molay F, Adams JM, Sachs GS, Hall JE.
  Longitudinal follow-up of reproductive and metabolic features of valproate-associated polycystic ovarian syndrome features: A preliminary report.
  Biol Psychiatry. 2006 Dec 15;60(12):1378-81. Epub 2006 Sep 1.
• Welt CK, Gudmundsson JA, Arason G, Adams J, Palsdottir H, Gudlaugsdottir G, Ingadottir G, Crowley WF.
  Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features.
  J Clin Endocrinol Metab. 2006 Dec;91(12):4842-8. Epub 2006 Sep 26.

back to top

Pediatrics

• Jones KL.
  The dilemma of the metabolic syndrome in children and adolescents: disease or distraction?
  Pediatr Diabetes. 2006 Dec;7(6):311-21.
• Ventura AK, Loken E, Birch LL.
  Risk profiles for metabolic syndrome in a nonclinical sample of adolescent girls.
  Pediatrics. 2006 Dec;118(6):2434-42.

back to top

Renal Function

• Axelsson J, Moller HJ, Witasp A, Qureshi AR, Carrero JJ, Heimburger O, Barany P, Alvestrand A, Lindholm B, Moestrup SK, Stenvinkel P.
  Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD.
  Am J Kidney Dis. 2006 Dec;48(6):916-25.
• Calo LA.
  Impact of metabolic syndrome on chronic kidney disease.
  Minerva Med. 2006 Dec;97(6):451-459.
• de Vinuesa SG, Goicoechea M, Kanter J, Puerta M, Cachofeiro V, Lahera V, Gomez-Campdera F, Luno J.
  Insulin Resistance, Inflammatory Biomarkers, and Adipokines in Patients with Chronic Kidney Disease: Effects of Angiotensin II Blockade.
  J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S206-12.

back to top

Risk Factors

• Boulon C, Lafitte M, Richeboeuf V, Paviot B, Pradeau V, Coste P, Bonnet J, Couffinhal T.
  Prevalence of metabolic syndrome after acute coronary syndrome and its prognostic significance.
  Am J Cardiol. 2006 Dec 1;98(11):1429-34. Epub 2006 Oct 4.
• Guldiken S, Tuncbilek N, Okten OO, Arikan E, Tugrul A.
  Visceral fat thickness determined using ultrasonography is associated with anthropometric and clinical parameters of metabolic syndrome.
  Int J Clin Pract. 2006 Dec;60(12):1576-81. Epub 2006 Mar 27.
• Metascreen Writing Committee; Bonadonna RC, Cucinotta D, Fedele D, Riccardi G, Tiengo A.
  The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey.
  Diabetes Care. 2006 Dec;29(12):2701-7.

back to top